相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Singapore serves as the pilot site for Roche's global effort to accelerate precision medicine in cancer treatment, leveraging the country's strong research and clinical capabilities. - Roche partnered with the National Cancer Centre Singapore and National University Cancer Institute, Singapore to extend comprehensive genomic profiling to more than 2,500 cancer patients. - The collaborations aim to give patients early access to targeted treatments, better diagnoses, and improved disease prevention. - The initiatives align with Singapore's RIE2025 focus on human health, strengthening the country as a global biomedtech and biomanufacturing hub.
- Professor Alexandre Chan has been appointed Director of Cancer Survivorship and Wellness at the National Cancer Centre Singapore (NCCS). - Prof Chan joins NCCS from the University of California Irvine, where he served as founding Chair of the Department of Clinical Pharmacy Practice. - As President of the Multinational Association of Supportive Care in Cancer (MASCC), Prof Chan brings expertise in supportive care, survivorship, and integrative oncology. - He will lead NCCS's growth in clinical, research, and educational excellence across survivorship, integrative oncology, and rehabilitation.
- A 32-year-old Singaporean singer with a rare spinal ependymoma experienced three recurrences over a decade, with the final tumour reaching 23 cm and becoming inoperable. - Proton beam therapy at the Goh Cheng Liang Proton Therapy Centre at NCCS delivered 28 sessions, precisely targeting the tumour while sparing the heart, lungs, liver, kidneys, and bowels. - A follow-up MRI in January 2026 showed no active tumour growth, and the patient regained leg sensation, balance, and mobility, completing a four-hour hike post-treatment. - Radiation oncologist Dr. Sharon Poh noted that prior surgeries were debulking only, and complete treatment should have included radiation therapy after surgery to prevent recurrence.
- The second ESMO Targeted Anticancer Therapies Asia Congress drew nearly 600 attendees to Hong Kong from June 12–14, 2026, reinforcing the region's role in early-phase oncology drug development. - Prof. Rui-Hua Xu delivered a keynote on emerging molecular targets and drugs for gastric cancer, highlighting new pipeline candidates, particularly from China. - A dedicated session on theranostics and radioligand therapy emphasized that building infrastructure, multidisciplinary expertise, and region-specific evidence is critical for translating innovation into patient outcomes. - The final day featured discussions on AI-driven applications in early drug development, balancing excitement with calls for rationality amid the hype.
- The Biomarkers and Precision Oncology Forum (BPOF) 2026 will host an Agnostic Molecular Tumor Board segment on July 30, 2026, in Singapore, where molecular profiles guide clinical decisions over organ of origin. - Moderator Dr. Nitesh Rohatgi will lead panelists Dr. Aparna Dhar, Dr. Chiang Jianbang, Dr. Jason Chan, and Dr. Tan Ya Hwee in deliberating complex cases through a tumour-agnostic lens. - Featured speakers include Dr. Shaheenah Dawood on endocrine therapy in HR+ breast cancer, Dr. Jianbang Chiang on NF1/NF2 targeted therapeutics, and Dr. Tan Ya Hwee on cell therapy in solid tumors. - The forum is accredited for 4 CME credits by the Singapore Medical Council and 4 CPE credits by the Singapore Nursing Board, with registration currently open.
- Singapore will conduct a clinical study involving 1,000 high-risk participants in the second half of 2026 to evaluate multi-cancer early detection (MCED) tests, which use liquid biopsies to screen for multiple cancers in a single blood test. - The study addresses the lack of evidence for MCED test performance in Asian populations, as most existing trials were conducted in predominantly Caucasian populations with different cancer epidemiology and genetic architecture. - A second study called CRAnE will focus on targeted screening for cancers linked to metabolic dysfunctions such as diabetes, obesity, and high cholesterol in primary care settings. - Both studies are launched by the newly established Research Institute for Cancer Prevention, Screening and Early Detection (RISE), jointly led by National Cancer Centre Singapore and Nanyang Technological University's medical school.
- Two Singapore-led clinical trials have identified promising new treatment approaches for difficult-to-treat women's cancers, including clear cell ovarian cancer and triple negative breast cancer. - The Lara trial showed that combining pembrolizumab and lenvatinib resulted in 40% of patients experiencing significant tumor shrinkage within 24 weeks for recurrent clear cell cancers. - A separate study found that datopotamab deruxtecan doubled progression-free survival to 10.8 months in triple negative breast cancer patients compared to standard chemotherapy. - Both treatments are currently under regulatory review, with researchers working to make these therapies available to patients in Singapore and internationally.
- A novel combination therapy using DNMT inhibitors with anti-PD-1 antibody sintilimab achieved complete remission in 10 of 21 patients with relapsed/refractory natural killer/T-cell lymphoma. - The treatment strategy leverages viral mimicry by reactivating endogenous retroviral elements to transform immunologically "cold" tumors into "hot" tumors susceptible to immune attack. - Patients treated with the combination therapy achieved a two-year overall survival rate of 50.2%, representing a significant improvement over the three-month benchmark for disease progression after anti-PD-1 treatment. - Preclinical studies demonstrated that DNMT inhibitors reverse immune resistance by activating type 1 interferon signaling and recruiting CD8-positive T cells into the tumor microenvironment.
- National Cancer Centre Singapore is currently conducting 40 active clinical trials across diverse cancer types including lung, breast, liver, bladder, and hematologic malignancies. - The trials feature innovative treatment approaches including antibody-drug conjugates, CAR-T cell therapies, and combination immunotherapy regimens targeting various molecular pathways. - Notable studies include Phase III trials of disitamab vedotin for HER2-positive urothelial carcinoma and tarlatamab for limited-stage small-cell lung cancer. - The comprehensive trial portfolio demonstrates Singapore's commitment to advancing cancer research and providing patients access to cutting-edge experimental therapies.
- Singapore will commence clinical trials of histotripsy, a non-invasive ultrasound-based cancer treatment that uses microbubbles to destroy tumors without surgery or radiation, starting in the second half of 2025. - The Li Ka Shing Foundation and Temasek Trust have committed S$12 million to bring two histotripsy machines to Singapore, with initial trials focusing on 40 liver cancer patients before expanding to kidney and pancreatic cancers. - Histotripsy, which received FDA approval for liver tumors in October 2023, has already treated approximately 50 cancer patients in Hong Kong and over 1,000 in the US, with researchers noting its potential to stimulate immune responses against non-targeted tumors.
